Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Lipid Modulation in Heart Failure: A Narrative Review. [PDF]
Neshat S +6 more
europepmc +1 more source
Comment on "The impact of dynamic kidney function prior to using sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients with low-risk renal disease progression". [PDF]
Sah SS, Kumbhalwar A.
europepmc +1 more source
Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus
Panai Song +3 more
openalex +1 more source
GABAergic mechanisms of excitation and hypersynchrony in adult rat hippocampus [PDF]
Uusisaari, Marylka
core
Chronic Kidney Disease in Metabolic Disease: Regulation of SGLT2 and Transcriptomic-Epigenetic Effects of Its Pharmacological Inhibition. [PDF]
Salvà C, Kaser S, Landolfo M.
europepmc +1 more source
Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors for Uricosuria. [PDF]
Bae E.
europepmc +1 more source
Comparing the Long-Term Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors Versus Mineralocorticoid Receptor Antagonists as Add-On Therapies in the Management of Heart Failure: A Systematic Review. [PDF]
George V +5 more
europepmc +1 more source
Effects of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and nonalcoholic fatty liver disease: A cohort study. [PDF]
Naguib R, Aleyeidi N, Naguib H.
europepmc +1 more source

